SCHEMBL6325883

SCHEMBL6325883

C[C@H](CO)N(C)S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 2/20 0.52
PSEN2 P49810 2/20 0.52
APH1B Q8WW43 2/20 0.52
NCSTN Q92542 2/20 0.52
APH1A Q96BI3 2/20 0.52
PSENEN Q9NZ42 2/20 0.52
AGER Q15109 1/20 0.45
KMT2A Q03164 5/20 0.44
MEN1 O00255 3/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP1 P03956 1/20 0.41
MMP7 P09237 1/20 0.41
MMP8 P22894 1/20 0.41
MMP12 P39900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325881 1.00 PSEN1 (0.52) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6321475 0.85 ESR1 (0.49) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6321479 0.85 ESR1 (0.49) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL13035726 0.82 AGER (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6323686 0.81 ADAMTS4 (0.62) MMP1MMP7MMP8MMP12MMP13
SCHEMBL6325694 0.81 MEN1 (0.57) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6323684 0.81 ADAMTS4 (0.62) MMP1MMP7MMP8MMP12MMP13
SCHEMBL6325691 0.81 MEN1 (0.57) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6330962 0.78 CA12 (0.49) KMT2AMEN1LMNAGAATSHR
SCHEMBL6330960 0.78 CA12 (0.49) KMT2AMEN1LMNAGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 PSEN1 893/4885PSEN2 1105/4885APH1B 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.